Brief: Ipa’S Subsidiary Biostrand And Briacell Announce Artificial Intelligence Collaboration And License Agreement To Discover And Develop Anti-Cancer Antibodies
30/11/2022 13:09
Nov 30 (Reuters) - Briacell Therapeutics Corp BCT.TO :
* IPA’S SUBSIDIARY BIOSTRAND AND BRIACELL ANNOUNCE
ARTIFICIAL
INTELLIGENCE COLLABORATION AND LICENSE AGREEMENT TO DISCOVER AND
DEVELOP ANTI-CANCER ANTIBODIES
Source text for Eikon: ID:nBw8hQNj4a
Further company coverage: BCT.TO
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Briacell Therapeutics
See all newsBrief: Briacell Therapeutics Prices 1.45 Million Common Shares At $3.25 Per Share
Brief: Briacell Receives Positive Recommendation From Data Safety Monitoring Board (Dsmb) For Phase 3 Study In Metastatic Breast Cancer
Brief: Briacell Expands Pipeline To Include An Ovarian Cancer Immunotherapy Candidate, Bria-Ova+™
Brief: Briacell Phase 3 Bria-Imt™ Study Enrollment Surpasses 230 Patients
Brief: Briacell Adds Nyu Langone Health’S Perlmutter Cancer Center As Clinical Site In Pivotal Phase 3 Breast Cancer Study